ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2010
Proteomics as a guiding tool for more effective personalized therapy.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Multi-omics predicts radiotherapy response in small cell lung cancer patients receiving whole brain irradiation.Journal of applied clinical medical physics · 2026Article
- Label-Free Proteomics of Severe Acute Hepatitis of Unknown Origin in Children by High-Resolution Mass Spectrometry.ACS omega · 2024Article
- Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?Biomedicines · 2023Review
- SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.Frontiers in oncology · 2022Article
- Proteomic Analysis Reveals That Metformin Suppresses PSMD2, STIP1, and CAP1 for Preventing Gastric Cancer AGS Cell Proliferation and Migration.ACS omega · 2021Article
- Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics.Journal of gastrointestinal oncology · 2021Article
- Article
- Computer Tomography Radiomics-Based Nomogram in the Survival Prediction for Brain Metastases From Non-Small Cell Lung Cancer Underwent Whole Brain Radiotherapy.Frontiers in oncology · 2020Article
- Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis.Scientific reports · 2019Article
- Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Cell reports · 2017Article
- Article
- Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.Oncotarget · 2016Article
- M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh's ESCC and promotes proliferation and migration of ESCC cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Confronting the Care Delivery Challenges Arising from Precision Medicine.Frontiers in oncology · 2016Review
- Clinical implications of using molecular diagnostics for ovarian cancers.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
- Ovarian cancer biomarker discovery based on genomic approaches.Journal of cancer prevention · 2013Review
- Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors.Genome biology · 2013Article
- Ovarian cancer: can proteomics give new insights for therapy and diagnosis?International journal of molecular sciences · 2013Review
- Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Nature reviews. Cancer · 2013Article
- Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas.Molecular biology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer remains the deadliest gynecological malignancy in the Western world and is most often diagnosed at a rarely curable late stage. Examination of protein end points has been employed as an investigative mechanism to guide targeted therapy and to stratify ovarian cancer. Proteomics allows characterization of the proteins and the associated protein and peptide modifications. This has given us insight into the perturbations of signaling pathways within tumor cells and has improved the discovery of new drug targets and possible prognostic indicators of outcome and disease response to therapy. Development of validated assays that survey the genetic and/or proteomic make-up of an individual tumor will add greatly to the histological classification of the tumor and may lead to different treatment approaches tailored to the unique expression pattern of each individual patient. It is anticipated that application of proteomics may bring to reality the clinical adoption of molecular stratification, e.g. not, 'is the gene overexpressed?', but 'is the pathway upregulated?' This will be successful if validated peptide biomarkers are applied for patient selection prospectively and with inclusion of preplanned biological correlates. These events will guide future directions of proteomics as a selector and as a validator and will guide how we integrate proteomics information daily into patient care and into selecting therapy of advanced and recurrent ovarian cancer and other cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.